CONTEXT: Sex steroid hormones have been linked to fractures in older women. OBJECTIVE: To test the hypothesis that hormones measured over the menopausal transition predict fractures. SETTING: Seven US clinical centers. SUBJECTS AND MEASUREMENTS: Two thousand nine hundred sixty women (average age, 46.4 ± 2.7 years) who had at least two repeat hormone measures and prospective information on fractures. Fasting serum was collected annually for hormone assays. Estradiol (E2) was measured with a modified direct immunoassay. FSH and SHBG were measured with two-site chemiluminescence immunoassays. Hormones were lagged (visit year -1) and transformed using log base 2. Incident fractures were ascertained at each annual visit. All medications including hormone therapy were time varying covariates. Discrete survival methods were used. RESULTS: Five hundred eight (17.2%) women experienced an incident fracture over an average follow up of 8.8 ± 4.4 years. Women who experienced an incident fracture were more likely to be white, report high alcohol intake and diabetes, and less likely to report premenopausal status at baseline. A woman whose log E2 was twice that of another had a 10% lower risk of fracture independent of covariates, relative risk (95% CI) = 0.90 (0.82, 0.98). Neither FSH nor SHBG were associated with fractures. CONCLUSIONS: Serum E2 levels may help to identify women at higher risk of fractures over the menopausal transition. However, hormone assays must be standardized across laboratories for clinical implementation and further work is needed to define E2 thresholds.
CONTEXT: Sex steroid hormones have been linked to fractures in older women. OBJECTIVE: To test the hypothesis that hormones measured over the menopausal transition predict fractures. SETTING: Seven US clinical centers. SUBJECTS AND MEASUREMENTS: Two thousand nine hundred sixty women (average age, 46.4 ± 2.7 years) who had at least two repeat hormone measures and prospective information on fractures. Fasting serum was collected annually for hormone assays. Estradiol (E2) was measured with a modified direct immunoassay. FSH and SHBG were measured with two-site chemiluminescence immunoassays. Hormones were lagged (visit year -1) and transformed using log base 2. Incident fractures were ascertained at each annual visit. All medications including hormone therapy were time varying covariates. Discrete survival methods were used. RESULTS: Five hundred eight (17.2%) women experienced an incident fracture over an average follow up of 8.8 ± 4.4 years. Women who experienced an incident fracture were more likely to be white, report high alcohol intake and diabetes, and less likely to report premenopausal status at baseline. A woman whose log E2 was twice that of another had a 10% lower risk of fracture independent of covariates, relative risk (95% CI) = 0.90 (0.82, 0.98). Neither FSH nor SHBG were associated with fractures. CONCLUSIONS: Serum E2 levels may help to identify women at higher risk of fractures over the menopausal transition. However, hormone assays must be standardized across laboratories for clinical implementation and further work is needed to define E2 thresholds.
Authors: Li Sun; Yuanzhen Peng; Allison C Sharrow; Jameel Iqbal; Zhiyuan Zhang; Dionysios J Papachristou; Samir Zaidi; Ling-Ling Zhu; Beatrice B Yaroslavskiy; Hang Zhou; Alberta Zallone; M Ram Sairam; T Rajendra Kumar; Wei Bo; Jonathan Braun; Luis Cardoso-Landa; Mitchell B Schaffler; Baljit S Moonga; Harry C Blair; Mone Zaidi Journal: Cell Date: 2006-04-21 Impact factor: 41.582
Authors: Barry G England; George H Parsons; Russell M Possley; Daniel S McConnell; A Rees Midgley Journal: Clin Chem Date: 2002-09 Impact factor: 8.327
Authors: MaryFran R Sowers; Mary Jannausch; Daniel McConnell; Roderick Little; Gail A Greendale; Joel S Finkelstein; Robert M Neer; Janet Johnston; Bruce Ettinger Journal: J Clin Endocrinol Metab Date: 2006-01-10 Impact factor: 5.958
Authors: Hermien W Goderie-Plomp; Marjolein van der Klift; Willem de Ronde; Albert Hofman; Frank H de Jong; Huibert A P Pols Journal: J Clin Endocrinol Metab Date: 2004-07 Impact factor: 5.958
Authors: Joel S Finkelstein; Mei-Ling T Lee; MaryFran Sowers; Bruce Ettinger; Robert M Neer; Jennifer L Kelsey; Jane A Cauley; Mei-Hua Huang; Gail A Greendale Journal: J Clin Endocrinol Metab Date: 2002-07 Impact factor: 5.958
Authors: Karin C Wu; Susan K Ewing; Xiaojuan Li; Sigurður Sigurðsson; Vilmundur Guðnason; Deborah M Kado; Trisha F Hue; Gina N Woods; Annegreet G Veldhuis-Vlug; Eric Vittinghoff; Mone Zaidi; Clifford J Rosen; Thomas Lang; Tiffany Y Kim; Ann V Schwartz; Anne L Schafer Journal: J Clin Endocrinol Metab Date: 2021-09-27 Impact factor: 6.134
Authors: Taylor C Wallace; Shinyoung Jun; Peishan Zou; George P McCabe; Bruce A Craig; Jane A Cauley; Connie M Weaver; Regan L Bailey Journal: Menopause Date: 2020-08 Impact factor: 3.310